» Articles » PMID: 33396289

Histological Correlation for Radiofrequency and Microwave Ablation in the Local Control of Hepatocellular Carcinoma (HCC) Before Liver Transplantation: A Comprehensive Review

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Jan 5
PMID 33396289
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Radiofrequency ablation (RFA) and microwave ablation (MWA) are the most widely studied and applied ablation techniques for treating primary and secondary liver tumors. These techniques are considered curative for small hepatic tumors, with post-ablation outcomes most commonly assessed by an imaging follow up. However, there is increasing evidence of a discrepancy between radiological and pathological findings when ablated lesions are evaluated following liver resection or liver transplantation. A comprehensive review of the available literature reporting the complete pathological response (cPR) following RFA and MWA was performed to estimate the success rate and identify the factors associated with treatment failure. Following RFA, cPR is reported in 26-96% of tumors compared to 57-95% with MWA. Larger tumor size and vessels larger than 3 mm adjacent to the treated tumor are the most important factors identified by previous studies associated with viable residual tumors after RFA. Correlating post-ablation radiological studies with pathological findings shows that computed tomography (CT) and magnetic resonance imaging (MRI) have low sensitivity but high specificity for detecting residual viable or recurrent hepatocellular carcinoma (HCC) tumors. There are promising recent reports combining multiprobe ablation techniques with three-dimensional treatment planning software and stereotactic-aiming instrumentation to achieve more than 90% cPR in both small and large HCC tumors. In conclusion, the reported success for achieving cPR in HCC following RFA and MWA is highly variable in different studies and decreases with increasing lesion size and unfavorable tumor characteristics. Very few studies have reported a high rate of cPR. As these studies are single-center and retrospective, they need to be further validated and reproduced in other clinical settings.

Citing Articles

Identification of proliferative hepatocellular carcinoma using the SMARS score and implications for microwave ablation.

Zhou P, Bao Y, Chang D, Li J, An T, Shen Y Insights Imaging. 2024; 15(1):220.

PMID: 39254824 PMC: 11387277. DOI: 10.1186/s13244-024-01792-8.


Long-Term Follow-Up Data of Tumor-Induced Osteomalacia Managed with Surgery and/or Radiofrequency Ablation from a Single Center.

Memon S, Patel M, Lila A, Jadhav S, Sarathi V, Karlekar M Calcif Tissue Int. 2024; 115(3):242-250.

PMID: 38922426 DOI: 10.1007/s00223-024-01249-6.


New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.

Liu H, Wang C, Wang R, Cao H, Cao Y, Huang T Chin J Cancer Res. 2024; 36(2):167-194.

PMID: 38751435 PMC: 11090796. DOI: 10.21147/j.issn.1000-9604.2024.02.06.


Radiofrequency ablation versus microwave ablation for hepatocellular carcinoma with cirrhosis: a propensity score analysis.

Xiong Y, Zhang Y, Hu C Transl Cancer Res. 2024; 13(4):1807-1820.

PMID: 38737685 PMC: 11082659. DOI: 10.21037/tcr-23-1939.


Adjuvant holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST HCC trial).

Hendriks P, Rietbergen D, van Erkel A, Coenraad M, Arntz M, Bennink R Eur J Nucl Med Mol Imaging. 2024; 51(7):2085-2097.

PMID: 38329507 PMC: 11139702. DOI: 10.1007/s00259-024-06630-z.


References
1.
Agopian V, Harlander-Locke M, Ruiz R, Klintmalm G, Senguttuvan S, Florman S . Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg. 2017; 266(3):525-535. DOI: 10.1097/SLA.0000000000002381. View

2.
Seror O, Nkontchou G, Tran Van Nhieu J, Rabahi Y, Nahon P, Laurent A . Histopathologic comparison of monopolar versus no-touch multipolar radiofrequency ablation to treat hepatocellular carcinoma within Milan criteria. J Vasc Interv Radiol. 2014; 25(4):599-607. DOI: 10.1016/j.jvir.2013.11.025. View

3.
Brillet P, Paradis V, Brancatelli G, Rangheard A, Consigny Y, Plessier A . Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. AJR Am J Roentgenol. 2006; 186(5 Suppl):S296-305. DOI: 10.2214/AJR.04.1927. View

4.
Fisher R, Maluf D, Cotterell A, Stravitz T, Wolfe L, Luketic V . Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant. 2004; 18(5):502-12. DOI: 10.1111/j.1399-0012.2004.00196.x. View

5.
Morimoto M, Sugimori K, Shirato K, Kokawa A, Tomita N, Saito T . Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologic-histologic correlation during follow-up periods. Hepatology. 2002; 35(6):1467-75. DOI: 10.1053/jhep.2002.33635. View